[84]sorafenib vs. extra function. < 0.001). Furthermore, axitinib confirmed a favourable toxicity profile; just 14 (4%) versus 29 (8%) of sufferers needed to discontinue treatment because of AEs. The most frequent AEs in the axitinib arm had been diarrhoea (55%), hypertension (40%) and exhaustion (39%) [64]. Quality 3 and 4 Continue Reading